Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Phase III Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Jiayu Li
- Phone Number: ++86 0756 726399
- Email: Jiayu.li@trinomab.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230601
- The Second Hospital of Anhui Medical University
-
Hefei, Anhui, China, 230061
- Hefei First People's Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
Beijing, Beijing Municipality, China, 100044
- Peking University People's Hospital
-
Beijing, Beijing Municipality, China, 100070
- Beijing Tiantan Hospital affiliated to Capital Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510180
- Guangzhou First People's Hospital
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital of Southern Medical University
-
Guangzhou, Guangdong, China, 510120
- Guangdong Provincial Hospital of Chinese Medicine
-
Guangzhou, Guangdong, China, 510062
- The First Affiliated Hospital, Sun Yat-sen University
-
Guangzhou, Guangdong, China, 510150
- The Third Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, China, 511407
- The First Affiliated Hospital of Guangzhou Medical University
-
Shenzhen, Guangdong, China, 518025
- Shenzhen Second People's Hospital
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545007
- Liuzhou Worker's Hospital - Fourth Affiliated Hospital of Guangxi Medical University
-
-
Guizhou
-
Zunyi, Guizhou, China, 563000
- Affiliated Hospital of Zunyi Medical College
-
-
Hainan
-
Haikou, Hainan, China, 570311
- Hainan General Hospital
-
-
Hangzhou
-
Hangzhou, Hangzhou, China, 310014
- Zhejiang Provincial People's Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, China, 430062
- Zhongnan Hospital of Wuhan University
-
Wuhan, Hubei, China, 430030
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
-
Wuhan, Hubei, China, 430014
- The Central Hospital of Wuhan, Tongji Medical College Huazhong University of Science&Technology
-
-
Hunan
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
Hengyang, Hunan, China, 421010
- Affiliated Nanhua Hospital, University of South China
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330008
- The Second Affiliated Hospital of Nanchang University
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750003
- General Hospital of Ningxia Medical University
-
-
Shandong
-
Zibo, Shandong, China, 255499
- PKUCare Luzhong Hospital
-
-
Shanxi
-
Jinzhong, Shanxi, China, 030602
- The First People's Hospital of Jinzhong
-
Taiyuan, Shanxi, China, 030032
- Shanxi Academy of Medical Sciences - Shanxi Bethune Hospital (Shanxi Dayi Hospital)
-
Yuncheng, Shanxi, China, 044099
- Yuncheng Central Hospital - East Campus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Chinese male or female adults aged ≥ 18 years;
- Participants with dirty or contaminated wounds caused by various injury who require passive immunization as prophylaxis against tetanus;
- Participants who provide signed written informed consent form.
Exclusion Criteria:
- Known or suspected allergy to the investigational product or its excipients, or have a history of allergy to human immunoglobulin products or other therapeutic monoclonal immunoglobulins;
- Suspect or diagnosed as tetanus;
- Previously diagnosed as Immunoglobulin A (IgA) deficiency with anti-IgA antibodies
- Prior vaccination history of ≥ 3 doses of tetanus toxoid or tetanus toxoid- containing vaccine;
- Current alcohol abuse, drug abuse or drug addiction
Other protocol defined Inclusion/Exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TNM002
If randomized to TNM002, participant will receive a single IM gluteal injection of TNM002
|
Dosage Form: Injection, solution Route of administration: IM gluteal injection |
|
Active Comparator: Human tetanus immunoglobulin (HTIG)
If randomized to HTIG, participant will receive a single IM gluteal injection of HTIG
|
Dosage Form: Injection, solution Route of administration: IM gluteal injection |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With ∆Titers ≥0.01 IU/mL at 12 Hours Post-dose
Time Frame: Baseline up to 12 hours after receipt of study drug
|
The change of anti-tetanus neutralizing antibody titers from baseline were defined as ΔTiters, calculated as the post-administration antibody titers minus the baseline antibody titers.
The antibody protective level is ΔTiters ≥0.01 IU/mL.
|
Baseline up to 12 hours after receipt of study drug
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tetanus Protection Rate on Day 28 Post-dose
Time Frame: Up to 28 days after receipt of study drug
|
The tetanus protection rate is defined as 1 minus the incidence of tetanus in the study population.
The table presents the number of participants who remained free from clinical tetanus over the specified time frame.
|
Up to 28 days after receipt of study drug
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With ΔTiters ≥0.01 IU/mL on Days 3, 7, 28, and 90 Post-dose.
Time Frame: Up to 90 days after receipt of study drug
|
The change of anti-tetanus neutralizing antibody titers from baseline were defined as ΔTiters, calculated as the post-administration antibody titers minus the baseline antibody titers.
The antibody protective level is ΔTiters ≥0.01 IU/mL.
|
Up to 90 days after receipt of study drug
|
|
∆Titers at 12 Hours, and on Days 3, 7, 28 and 90 Post-dose
Time Frame: At 12 hours, and on Days 3, 7, 28 and 90 post-dose
|
The change of anti-tetanus neutralizing antibody titers were defined as ΔTiters, calculated as the post-administration antibody titers minus the baseline antibody titers.
The antibody protective level is ΔTiters >0.01 IU/mL.
|
At 12 hours, and on Days 3, 7, 28 and 90 post-dose
|
|
Tetanus Protection Rate on Days 90 and 105 Post-dose
Time Frame: Up to 105 days after receipt of study drug
|
The tetanus protection rate is defined as 1 minus the incidence of tetanus in the study population.
The table presents the number of participants who remained free from clinical tetanus over the specified time frame.
|
Up to 105 days after receipt of study drug
|
|
TNM002 Serum Concentration
Time Frame: pre-dose, 12h, and Days 3, 7, 28, 90 post-dose
|
Arithmetic mean concentrations of TNM002 at each specified timepoint
|
pre-dose, 12h, and Days 3, 7, 28, 90 post-dose
|
|
Anti-drug Antibodies (ADA) Against TNM002
Time Frame: pre-dose, and Days 7, 28, and 90 post-dose
|
The positive rate of ADA in the TNM002 group at each specified timepoint
|
pre-dose, and Days 7, 28, and 90 post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chuanlin Wang, MD, Peking University People's Hospital
- Study Director: Shengyi Wang, Zhuhai Trinomab Pharmaceutical Co., Ltd.
Publications and helpful links
General Publications
- Wang CL, Liu S, Shao ZJ, Yin ZD, Chen QJ, Ma X, Ma C, Wang Q, Wang LH, Deng JK, Li YX, Zhao ZX, Wu D, Wu J, Zhang L, Yao KH, Gao Y, Xie X. [Guidelines for the use of post-traumatic tetanus vaccines and passive immune preparation]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Dec 6;53(12):1212-1217. doi: 10.3760/cma.j.issn.0253-9624.2019.12.005. Chinese.
- Tetanus vaccines: WHO position paper - February 2017. Wkly Epidemiol Rec. 2017 Feb 10;92(6):53-76. No abstract available. English, French.
- Yu Chao, Xu Yuming, Xu Jin, et al. Progress of clinical application and safety of tetanus antitoxin. Chinese Journal of Pharmacovigilance, 2016, 13 (1): 36-41.
- Perey BJ. Progress in tetanus prophylaxis: the advent of human antitoxin. Can Med Assoc J. 1966 Feb 26;94(9):437-41.
- Plotkin, S.A., W.A. Orenstein and P.A. Offit, Plotkin's vaccines. Seventh edition. ed. 2018. 1691.
- Ortiz JR, Hombach J. Announcing the publication of the WHO immunological basis for immunization series module on influenza vaccines. Vaccine. 2018 Sep 5;36(37):5504-5505. doi: 10.1016/j.vaccine.2017.09.010. Epub 2017 Oct 16.
- Forrat R, Dumas R, Seiberling M, Merz M, Lutsch C, Lang J. Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of tetanus. Antimicrob Agents Chemother. 1998 Feb;42(2):298-305. doi: 10.1128/AAC.42.2.298.
- Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet. 2007 Dec 8;370(9603):1947-59. doi: 10.1016/S0140-6736(07)61261-6.
- Liang Z, Liu S, Guo W, Deng Z, Bin W, Yu A, Hu J, Wu L, Li Z, Huang W, Li H, Cheng D, Li S, Guo Q, Zhang D, Yan X, Wang C, Cai W, Ding B, Li W, Li X, Xu B, He L, Ouyang Y, Zhan H, Wang J, Zhao Y, Liu X, Xiang W, Zhang M, Zhang Z, Ding J, Kuang X, Zheng W, Liao H, Wang W, Wang C. Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial. Nat Med. 2025 Aug;31(8):2673-2681. doi: 10.1038/s41591-025-03791-8. Epub 2025 Jul 8.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TNM002-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.